VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022
Event: VistaGen Therapeutics Fiscal Year 2023 First Quarter Financial Results Conference Call
US Dial-in (Toll Free): 1-888-999-5318
Conference ID: 4956626
An audio webcast of the conference call will also be available via the link provided above. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately
VistaGen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. The Company is advancing drug candidates with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherine nasal sprays, which are investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.VistaGen.com.
Vice President, Investor Relations